Last reviewed · How we verify
NCT07535359
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
trial testing Ifinatamab Deruxtecan in SCLC. Temporarily not available.
Quick facts
| Lead sponsor | Daiichi Sankyo |
|---|---|
| Status | TEMPORARILY NOT AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Ifinatamab Deruxtecan — full drug profile →
Conditions studied
- SCLC — all drugs for SCLC →
- Extensive-stage Small Cell Lung Cancer — all drugs for Extensive-stage Small Cell Lung Cancer →
Sponsor
Daiichi Sankyo — full company profile →
Who can join
18 and older, any sex, with SCLC or Extensive-stage Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to I-DXd for eligible patients with extensive-stage small cell lung cancer (ES-SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen), and for eligible patients who have no suitable treatment options and are not able to enter a clinical study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07535359
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ifinatamab Deruxtecan
Trials testing the same drug.
- NCT06863272 — A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Re · Phase 1, PHASE2 · recruiting
- NCT06780085 — A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cance · Phase 2 · recruiting
Other recruiting trials for SCLC
Currently open trials in the same condition.
- NCT07110103 — Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC · Phase 2 · recruiting
- NCT07145333 — Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07508852 — 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
- NCT06616532 — PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer · Phase 3 · recruiting
- NCT06534762 — Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study · Phase 2 · recruiting
Other Daiichi Sankyo trials
Trials by the same sponsor.
- NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
- NCT07206472 — A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholestero · active not recruiting
- NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
- NCT07268625 — Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorv · Phase 1 · completed
- NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07535359 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daiichi Sankyo
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07535359.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing